Glycoprotein 330 (gp330) is an endocytic receptor expressed in the renal proximal tubules and some other absorptive epithelia, e.g., in the inner ear. The present study shows that the antifibrinolytic polypeptide, aprotinin, and the nephroand ototoxic antibiotics, aminoglycosides, and polymyxin B compete for binding of '"I-urokinase-plasminogen activator inhibitor type-i complexes to purified rabbit gp330. Half maximal inhibition was measured at 4 ,uM for aprotinin, 50 tiM for gentamicin, and 0.5 tiM for polymyxin B. Drug binding to gp330 was validated by equilibrium dialysis of [3H]gentamicin-gp330 incubations and binding/uptake studies in rat proximal tubules and gp330-expressing L2 carcinoma cells. Analyses of mutant aprotinins expressed in Saccharomyces cerevisiae revealed that basic residues are essential for the binding to gp330 and renal uptake. The polybasic drugs also antagonized ligand binding to the human a2-macroglobulin receptor. However, the rapid glomerular filtration of the drugs suggests kidney gp330 to be the quantitatively most important target.
Introduction
Glycoprotein 330 (gp330)l alias Heymann Nephritis autoantigen (1) and megalin (2) is an 600 kD (2-6) protein expressed in the renal tubule epithelium and a few other specialized epithelial cell types, e.g., retinal and inner ear epithelium 1 . Abbreviation used in this paper: a2MR/LRP, a2-macroglobulin receptor/LDL receptor-related protein; gp330, glycoprotein 330; PAI-1, plasminogen activator inhibitor type-i; RAP, receptor-associated protein. (7) (8) (9) . cDNA cloning (2, 10) has demonstrated that gp330 is a member of the LDL receptor family. This also includes the homologous 600-kD multiligand a2-macroglobulin receptor (a2MR) also called LDL receptor-related protein (LRP) ( for review see references 11, 12) . Both receptors are anionic proteins and gp330 has an estimated pI at 4.6 (13) . In contrast to gp330, a2MR/LRP is expressed in several cell types facing the circulation (e.g., mononuclear phagocytes and hepatocytes), while no expression is observed in gp330-expressing epithelia in the kidney and inner ear (7) (8) (9) 14) .
a2MR/LRP and gp330 bind Ca2' and several common ligands including plasminogen activators in complex with their type-i inhibitor (PAI-1), plasminogen, lipoprotein lipase, and the 39-40-kD receptor-associated protein (RAP) (4, 5, 6, (15) (16) (17) . Studies on a2MR/LRP suggest that charge interactions between basic regions of the ligands and negatively charged complement-type repeats (synonymous to LDL receptor-like repeats) are essential for ligand/receptor interaction (18, 19) .
Studies of the uptake of "2I-labeled RAP and urokinase PAI-i complexes in perfused rat and rabbit proximal tubules (4, 20) have established the function of gp330 as an endocytosis-mediating receptor of protein ligands. In addition to this function, the strong affinity for Ca2+ (4) and a suggested function as a Ca2+ sensor in the parathyroid glands (21) might indicate a role in the Ca2" homeostasis.
The cationic nature of several established ligands to gp330 led us to investigate gp330 binding of three main types of polybasic drugs known to accumulate in renal cortex. Aminoglycosides are antibiotics commonly used to treat gram-negative infections. Unfortunately, they are frequently associated with severe nephro-and ototoxicity as a direct consequence of lysosomal accumulation in the kidney proximal tubules and inner ear epithelium (22) (23) (24) (25) . Aminoglycosides are taken up in proximal tubules (SI and S2 segments) by a receptor-mediated mechanism as judged by electron microscopic localization of aminoglycosides in coated pits and endocytic compartments (23, 24, (26) (27) (28) . A common uptake mechanism in the ear and kidney has been suggested (29) . Acidic phospholipids are assumed to be the initial epithelial binding site (25) , but no endocytic receptors mediating uptake of aminoglycosides have so far been identified.
Aprotinin alias bovine pancreatic trypsin inhibitor is a 6-kD protein with a clinical potential in acute pancreatitis and antifibrinolytic therapy. Intravenously administrated aprotinin accumulates in the lysosomes of kidney proximal tubules (30, 31 ) and is only very slowly degraded (30) in accordance with xray crystallographic analysis of aprotinin demonstrating a highly compact and stable tertiary structure (32) .
Polymyxin B is a 1-kD polycationic cyclic peptide antibiotic with detergent effects on gram-negative bacteria. It also accumulates in the proximal tubules, and due to side effects such as nephrotoxicity, it is only recommended for external use (33, 34) . Besides its antimicrobial activity, polymyxin B is a potent inhibitor of endotoxin via binding to the lipid A part of endotoxin (35) .
In the present study we have investigated binding of aminoglycosides, e.g., gentamicin, aprotinin, and polymyxin B to gp330 and the uptake mediated via this receptor, as well as the binding to a2MR/LRP. In addition, a panel of recombinant aprotinin mutants with a diversity of net charges was analyzed. We find that the drugs bind to gp330 as well as to a2MR/LRP and provide evidence that the renal uptake occurs via gp330. By site-directed mutagenesis we show that the polybasic nature of aprotinin determines the affinity for the receptor.
Methods
Receptors, ligands andpolybasic drugs. Rabbit gp330 was purified from solubilized rabbit kidney cortex membranes by RAP-affinity chromatography (20) . Human two-chain a2MR/LRP was purified from solubilized membrane preparations from newborn placenta by a2-macroglobulinmethylamine-affinity chromatography (15) . RAP was produced as a recombinant protein in Escherichia coli transfected with cDNA encoding human RAP (36). Human urokinase-PAI-I complexes were kindly provided by Drs. A. Nykjwr and P. Andreasen, University of Aarhus, Denmark. Aprotinin and mutants were produced as recombinant proteins in Saccharomyces cerevisiae as described (37 In vivo uptake studies ofaprotinin mutants and gentamicin. Female Wistar rats, weighing 175-235 grams were used. An oral dose of 2 ml H20 was given before administration of the aprotinin mutants. The mutants were given intravenously as bolus injections into a tail vein using an intravenous catheter. After 3 h, the rats were killed by administration of CO2 into the cage, and the kidneys were removed and stored at -80°until analysis. During CO2 administration, the rats emptied the urinary bladder. The metabolism cages used were rinsed with 0.9% NaCl to obtain a total urine-NaCl volume at 10 ml.
The levels of aprotinin and mutants in urine, plasma, kidney, and liver homogenates were measured photometrically by using an assay for kallikrein inhibitory activity (37 with aprotinin, probably due to the presence of multiple RAP binding sites in each receptor (20, 41) . Renal gp330-mediated binding and endocytosis ofaprotinin and mutants. The investigation of gp330 binding and renal handling of aprotinin included a comparative analysis with a panel of recombinant aprotinin mutants with a variety of net charges expressed in S. cerevisiae (Table I) .
"lI-aprotinin bound specifically to the proximal tubules epithelium ( Fig. 2) as assessed by binding to rat kidney cortex sections and light microscopic autoradiography. The autoradiographic grains representing bound '25I-aprotinin were localized over the epithelium of the proximal tubule cells, whereas virtually no grains were observed over distal tubules and collecting hibitory mutants) and decreased structural stability. Compared to native aprotinin, the mutants had decreased thermostability (Table I ) and stability in kidney lysates (not shown) as measured by the kallikrein-inhibitory activity.
Gp330-mediated endocytosis of aprotinin and two of the mutants was examined in the rat yolk sac carcinoma cell line L2, which expresses gp330 (42) but virtually no a2MR/LRP (43) . As shown in Fig. 3, 1251I -aprotinin was rapidly endocytosed in a RAP-inhibitable manner and accumulated in lysosome-like vesicles of L2 cells (Fig. 4) . The mutant KFN 324 was also endocytosed in accordance with its binding to gp330 (Tables  H and III) . However, in contrast to wild-type aprotinin, it was degraded to a much higher extent probably due a decreased structural stability (Table I) Fig. 5) .
Indirect evidence for binding of gentamicin as well as polymyxin B to cell surface gp330 was obtained by the inhibition of the uptake of 251I-aprotinin (Fig. 6) Table V) . The increase in urinary excretion was highly significant (P < 0.01).
Discussion
In the present report we have provided evidence that epithelial gp330 is a receptor for three types of polybasic drugs (aprotinin, aminoglycosides, and polymyxin B) used in human therapy. The data also show an antagonizing effect of the drugs on ligand binding to the homologous receptor, a2MR/LRP. However, the rapid filtration of the drugs in the glomeruli suggests only a minor uptake in a2MR/LRP-bearing cells facing the circulation. Accordingly, we observed that 44% of intravenously injected aprotinin was recovered in the kidney after 3 h while the content in the liver was 10-fold lower. On their way through the kidney proximal tubules, filtered molecules are exposed to a high density of surface-expressed gp330 (1, 7) . SDS-PAGE of whole cortex (4) has shown that gp330 accounts for a substantial part, maybe several percent of the total mass of apical membrane protein. The high density of gp330 combined with the length of tubules and concentration of the fluid suggest a high number of collisions between gp330 and filtered molecules. On this basis, gp330 might account for the renal uptake of a number of basic molecules with low affinity charge interactions with gp330. Previous studies have shown that cationic proteins are reabsorbed much more efficiently than anionic proteins (44) (45) (46) .
The mechanism for uptake of polybasic drugs, in particular aminoglycosides, has previously been studied by several groups. In agreement with our data, Just et al. (30) found that aminoglycosides compete for the binding of aprotinin to isolated renal brush border membrane and a common type of binding site for the two drugs was proposed. Using autoradiographic techniques (24, 28) and an immunocytochemical approach (26) , gentamicin has been shown to bind to the apical membrane in the proximal tubule, concentrate in coated pits followed by uptake into endocytic compartments. No membrane receptor has so far been shown to be involved in this binding and uptake. Sastrasinh et al. (47) showed binding of aminoglycosides to acidic phospholipids (25) . The Kd for binding of gentamicin to phosphatidylinositol is 170 /iM (48) , which is a lower affinity compared to the apparent affinity for gp330 (half maximal inhibition of '251-urokinase-PAI-l binding at 50 /iM gentamicin). However, the receptor affinity of gentamicin and the other polybasic drugs are lower compared to endogenous gp330 ligands, which have Kd 's in the nanomolar range ( 1 1 ). Accordingly, the solid phase '251-urokinase-PAI-1 binding assay in Fig. 1 with a limited amount of receptors immobilized in microtiter wells, was not suitable for measuring direct binding of radiolabeled drugs.
Phospholipids are undoubtedly more widely distributed on the epithelial surface compared to gp330, which main membrane location is in coated pits (1) . Initial binding to acidic phospholipids and subsequent delivery to gp330 might therefore be the principal route for receptor-mediated uptake of aminoglycosides (Fig. 8) . This model is consistent with the previous autoradiographic studies of aminoglycoside uptake in the kidney (24, 28) or uptake has been shown for the uptake of urokibind to nonendocytic membrane components (urokinase recepid lipoprotein lipase via a2MR/LRP. Both ligands tor and proteoglycans, respectively) but are subsequently bound and endocytosed via a2MR/LRP (36, 49, 50) . The hypothesis of a direct connection between gp330-mediated endocytosis of aminoglycosides and their nephrotoxic effect is supported by the fact, that the nephrotoxic effects occurs primarily in the S1 and S2 segments, the same part of the nephron as gp330 preferentially is expressed (51) . Furthermore, the apparent gp330 affinities of the aminoglycosides are in the order of gentamicin, netilmicin, and kanamicin, which agrees with their number of dissociable amino groups and nephrotoxic potential (25) . Previous studies have shown uptake, lysosomal accumulation, and toxic effect of aminoglycosides in other cell types as fibroblasts (52) , retinal pigment epithelium (53), and cochlea (22, 54) . Fibroblasts have a high expression of a2MR/LRP (14, 55) whereas retinal pigment cells (8) and the inner ear epithelium express gp330 (9) . Future studies should in particular explore the role of cochlear gp330 for the uptake of amino-100 The values in columns 2 and 3 display the percentage of injected dose (2,000 cpm) collected in the urine for 40 min. Each of four tubules was infused with and without 2 mM gentamicin. In experiments 3 and 4 injection with gentamicin was carried out before the perfusion without gentamicin and in the two other experiments the order was reversed as described in Methods. The urinary content of 1"I-aprotinin was significantly higher when gentamicin was present in the injection fluid (P < 0.01 by the method of paired comparison). domains, e.g., amyloid precursor protein are processed via gp330 or a2MR/LRP. However, the present data do not suggest that the common feature of having Kunitz domains is the reason that aprotinin and TFPI apparently bind to the same receptors, since two of the basic aprotinin residues (Lys46 and ArgI7) essential for receptor binding are located outside the Kunitz domain of aprotinin (32) .
Polymyxin B was the drug with the highest inhibitory potential on ligand binding to gp330 and a2MR/LRP and it seems likely that gp330-mediated endocytosis is associated with its nephro-and ototoxic effect (33, 34) . The binding sites for polymyxin B in the proximal tubules and the cochlear epithelium have not previously been characterized but other studies have shown specific Ca2+-dependent uptake of polymyxin B in macrophages, hepatocytes, fibroblasts, and smooth muscle cells via a receptor-mediated pathway not dependent of the LDLreceptor or asialoglycoprotein receptor (57-59). a2MR/LRP is highly expressed in these cell types (14) .
In conclusion we have shown a novel role of gp330 as a drug receptor and provided new insight into the molecular mechanism for uptake of polybasic drugs. In view of the severe therapeutic side effects in the kidney and ear caused by lysosomal accumulation of polybasic drugs, in particular aminoglycosides, it would be interesting to explore the possibility of a selective inhibition of receptor-mediated drug uptake not disturbing the antibiotic effect.
